AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2667860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 913875 — intervention group
Group type: EXPERIMENTAL
Intervention: Safapryn
Number of subjects: 11
Study 913875 — intervention group
Group type: COMPARATOR
Intervention: Butazolidin
Number of subjects: 11
Study 31087313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum (0.2 mL, 0.1 mL on either side, every 2 hours for 72 hours)
Number of subjects: 117
Study 31087313 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 117
Study 31010430 — intervention group
Group type: EXPERIMENTAL
Intervention: LAFEW 8 g group
Number of subjects: 22
Study 31010430 — intervention group
Group type: EXPERIMENTAL
Intervention: LAFEW 6 g group
Number of subjects: 22
Study 31010430 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 g of milk whey protein)
Number of subjects: 22
Study 28479240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 0
Study 28479240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26466123 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 20
Study 26466123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23820680 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow gastric tube reconstruction
Number of subjects: 104
Study 23820680 — intervention group
Group type: COMPARATOR
Intervention: Whole stomach reconstruction
Number of subjects: 104
Study 21442610 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal and multidisciplinary perioperative care protocol
Number of subjects: 0
Study 21442610 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (historical and concurrent national controls)
Number of subjects: 0
Study 19558521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) on mode
Number of subjects: 35
Study 19558521 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) off mode
Number of subjects: 35
Study 17729170 — intervention group
Group type: EXPERIMENTAL
Intervention: High utilizers (HU)
Number of subjects: 500
Study 17729170 — intervention group
Group type: COMPARATOR
Intervention: Low utilizers (LU)
Number of subjects: 500
Study 15132312 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 29
Study 15132312 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 29
Study 12047395 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 9830818 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational letter
Number of subjects: 732
Study 9830818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study 8172113 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex dietary patterns
Number of subjects: 0
Study 8172113 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific combinations of nutrients
Number of subjects: 0
Study 8172113 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nutrients with antihypertensive properties
Number of subjects: 0
Study 8172113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns
Number of subjects: 0
Study 2697484 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (PB) therapy
Number of subjects: 0
Study 2697484 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study 2697484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas (SU) plus metformin (M)
Number of subjects: 0
Study 2697484 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study 341301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuterol 0.75 mg
Number of subjects: 16
Study 341301 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.50 mg
Number of subjects: 16
Study 30827757 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rTMS
Number of subjects: 27
Study 30827757 — intervention group
Group type: COMPARATOR
Intervention: Intermittent theta-burst (iTBS)
Number of subjects: 27
Study 30827757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rTMS interventions
Number of subjects: 27
Study 29082824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LF) stimulation
Number of subjects: 20
Study 29082824 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26896960 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance program (12-month, 22-session intervention)
Number of subjects: 223
Study 25134980 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE screening program
Number of subjects: 31
Study 22245896 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 602
Study 22245896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study 19861328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh ICSI insemination
Number of subjects: 40
Study 19861328 — intervention group
Group type: COMPARATOR
Intervention: Vitrification procedure
Number of subjects: 40
Study 19861328 — intervention group
Group type: COMPARATOR
Intervention: Vitrification cycles
Number of subjects: 40
Study 17375982 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 158
Study 16045526 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient microwave endometrial ablation (MEA) in the postmenstrual phase
Number of subjects: 210
Study 16045526 — intervention group
Group type: COMPARATOR
Intervention: Standard MEA treatment after drug preparation
Number of subjects: 210
Study 12230594 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-99 6.25 mg t.i.d.
Number of subjects: 147
Study 12230594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 12230594 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-99 (2.08 mg; 6.25 mg; 18.75 mg t.i.d.)
Number of subjects: 147
Study 12230594 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-99
Number of subjects: 147
Study 12230594 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 147
Study 10025454 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with intravenous conscious sedation and monitored anesthesia care
Number of subjects: 48
Study 10025454 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 48
Study 10025454 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 48
Study 10025454 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia and General anesthesia
Number of subjects: 48
Study 7788826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 morphine plus 3 micrograms.kg‐1 clonidine (M+C group; n = 10)
Number of subjects: 20
Study 7788826 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg.kg‐1 morphine alone (M group; n = 10)
Number of subjects: 20
Study 7788826 — intervention group
Group type: EXPERIMENTAL
Intervention: M+C group
Number of subjects: 20
Study 2204698 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine (40 or 80 micrograms)
Number of subjects: 15
Study 2204698 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 15
Study 2204698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2204698 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hepatitis B vaccine and placebo)
Number of subjects: 15
Study 913279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophenazone in children with acute viral hepatitis
Number of subjects: 23
Study 913279 — intervention group
Group type: COMPARATOR
Intervention: Aminophenazone in healthy children (control group)
Number of subjects: 23
Study 913279 — intervention group
Group type: COMPARATOR
Intervention: Aminophenazone two hours after oral intake in healthy children (control group)
Number of subjects: 23
Study 31571367 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation combined with topical 5% 5-flurouracil application followed by NB‐UVB sessions for 4 months
Number of subjects: 40
Study 31571367 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB sessions for 4 months (control side)
Number of subjects: 40
Study 31012565 — intervention group
Group type: EXPERIMENTAL
Intervention: Red deer mesenchymal stem cell extract (RCE) cream
Number of subjects: 40
Study 31012565 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40
Study 28337716 — intervention group
Group type: EXPERIMENTAL
Intervention: high volume on-line hemodiafiltration (hv-OL-HDF)
Number of subjects: 36
Study 28337716 — intervention group
Group type: COMPARATOR
Intervention: low-flux bicarbonate dialysis (BHD)
Number of subjects: 36
Study 25023183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated return to player
Number of subjects: 128
Study 25023183 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 90% return to player
Number of subjects: 128
Study 25023183 — intervention group
Group type: COMPARATOR
Intervention: Control (no practice)
Number of subjects: 128
Study 25023183 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated return with pop‐up messages
Number of subjects: 128
Study 24145742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (10 g over 3 to 5 days, or 8 g over 2 days)
Number of subjects: 564
Study 24145742 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 564
Study 22111516 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry (BB) ingestion (250 g per day for 6 weeks and 375 g 1 hour prior to exercise)
Number of subjects: 25
Study 22111516 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 25
Study 19927100 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-L (TDR) at L4/5
Number of subjects: 200
Study 19927100 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-L (TDR) at L5/S1
Number of subjects: 200
Study 19927100 — intervention group
Group type: COMPARATOR
Intervention: First cranial adjacent segment to fusion at L5/S1
Number of subjects: 200
Study 19927100 — intervention group
Group type: EXPERIMENTAL
Intervention: First caudal segment below TDR at L4/5
Number of subjects: 200
Study 19927100 — intervention group
Group type: COMPARATOR
Intervention: First caudal segment below fusion at L4/5
Number of subjects: 200
Study 16987338 — intervention group
Group type: EXPERIMENTAL
Intervention: HES200/0.5
Number of subjects: 60
Study 16987338 — intervention group
Group type: EXPERIMENTAL
Intervention: HES130/0.4
Number of subjects: 60
Study 16987338 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group L)
Number of subjects: 60
Study 12722962 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 25 mg
Number of subjects: 24
Study 12722962 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 60 mg and 120 mg
Number of subjects: 24
Study 10657410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic (HV) therapy
Number of subjects: 82
Study 10657410 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic (NV) therapy
Number of subjects: 82
Study 10657410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HV and NV therapy
Number of subjects: 82
Study 9071714 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (750 anti-Xa units subcutaneously once-daily for 6 weeks)
Number of subjects: 9
Study 9071714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9071714 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid sodium
Number of subjects: 9
Study 8369391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric confidence interval procedure for the difference or ratio of two median failure times
Number of subjects: 0
Study 2428948 — intervention group
Group type: EXPERIMENTAL
Intervention: VAB-6 chemotherapy regimen (cyclophosphamide, vinblastine, bleomycin, dactinomycin, and cisplatin)
Number of subjects: 166
Study 2428948 — intervention group
Group type: EXPERIMENTAL
Intervention: VAB-6 chemotherapy regimen
Number of subjects: 166
Study 29139056 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR), a 10-week home visiting parenting intervention
Number of subjects: 0
Study 28577676 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urinary creatinine measurement
Number of subjects: 2130
Study 25714016 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA RP11‐160H22.5, XLOC_014172, LOC149086
Number of subjects: 0
Study 25714016 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNA XLOC_014172, LOC149086
Number of subjects: 0
Study 25714016 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operation levels of lncRNAs RP11‐160H22.5, XLOC_014172, LOC149086
Number of subjects: 0
Study 25885841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 2 mg/kg body weight with 50 μg fentanyl
Number of subjects: 60
Study 25885841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% at 2 mg/kg body weight with 100 μg fentanyl
Number of subjects: 60
Study 21962070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron(III)‐hydroxide sucrose (200 mg)
Number of subjects: 24
Study 21962070 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 24
Study 18243822 — intervention group
Group type: EXPERIMENTAL
Intervention: SPE‐LC‐MS/MS
Number of subjects: 0
Study 18243822 — intervention group
Group type: COMPARATOR
Intervention: SPE‐LC‐UV
Number of subjects: 0
Study 16784008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ze 339
Number of subjects: 18
Study 16784008 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine
Number of subjects: 18
Study 16784008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15021764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal balloon inflation during descent
Number of subjects: 188
Study 15021764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal balloon inflation)
Number of subjects: 188
Study 15021764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal balloon inflation after negative pressure
Number of subjects: 188
Study 15021764 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva's maneuver
Number of subjects: 188
Study 10697085 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous (AV) impulse system
Number of subjects: 143
Study 10697085 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg)
Number of subjects: 143
Study 9176645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 0.8 mg b.i.d.
Number of subjects: 5
Study 8222166 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (3 g/d)
Number of subjects: 20
Study 8222166 — intervention group
Group type: COMPARATOR
Intervention: omega-6 fatty acids (placebo group)
Number of subjects: 20
Study 2871333 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 20
Study 2871333 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 2871333 — intervention group
Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 20
Study 2871333 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 20
Study 31777160 — intervention group
Group type: EXPERIMENTAL
Intervention: LA emptying fraction (LAEF)
Number of subjects: 971
Study 31777160 — intervention group
Group type: EXPERIMENTAL
Intervention: LA expansion index (LAEi)
Number of subjects: 971
Study 31777160 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher left atrial volume index (LAVi)
Number of subjects: 971
Study 31777160 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of CV death or HF hospitalization
Number of subjects: 971
Study 29846017 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME)
Number of subjects: 799
Study 29846017 — intervention group
Group type: COMPARATOR
Intervention: Postoperative CRT
Number of subjects: 799
Study 29846017 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomotic leakage
Number of subjects: 799
Study 29846017 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired wound healing
Number of subjects: 799
Study 29846017 — intervention group
Group type: EXPERIMENTAL
Intervention: Any surgical complication (anastomotic leakage and/or wound healing disorder)
Number of subjects: 799
Study 27227544 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT-hemoporfin (532 nm laser irradiation at 96‐120 J/cm2 with hemoporfin 5mg/kg)
Number of subjects: 440
Study 27227544 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT-hemoporfin
Number of subjects: 440
Study 27227544 — intervention group
Group type: COMPARATOR
Intervention: PDT-placebo (irradiation with placebo)
Number of subjects: 440
Study 23575211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU twice per week
Number of subjects: 87
Study 23575211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 22734374 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture before kinesitherapy (Group A)
Number of subjects: 29
Study 22734374 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy before acupuncture (Group B)
Number of subjects: 29
Study 22734374 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 29
Study 20624511 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 284
Study 20624511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 18388017 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 18388017 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 16036503 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SST) 500 microg/h + 250 microg bolus
Number of subjects: 43
Study 16036503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (PAN) 8 mg/h + 80 mg bolus
Number of subjects: 43
Study 16036503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) normal saline
Number of subjects: 43
Study 12585170 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhongfeng No. II Oral Liquid (ZF II) plus western medicine
Number of subjects: 160
Study 12585170 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone (control group)
Number of subjects: 160
Study 12585170 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhongfeng No. II Oral Liquid (ZF II) in animal model
Number of subjects: 160
Study 12585170 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group in animal model)
Number of subjects: 160
Study 11096246 — intervention group
Group type: COMPARATOR
Intervention: Supine position (group 1)
Number of subjects: 96
Study 11096246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (group 2)
Number of subjects: 96
Study 9312759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (75 g) and i.v. glucagon test (1 mg)
Number of subjects: 100
Study 10603808 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo method (K)
Number of subjects: 61
Study 10603808 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (T)
Number of subjects: 61
Study 3827456 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg/d for four weeks)
Number of subjects: 10
Study 3827456 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (25 mg/d for four weeks)
Number of subjects: 10
Study 30477836 — intervention group
Group type: EXPERIMENTAL
Intervention: Painting and handcrafting group art therapy (creative art therapy) for one month
Number of subjects: 60
Study 30477836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 26768748 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise at high intensity and individual coaching for 3 months, followed by self-managed physical activity for 9 months.
Number of subjects: 35
Study 25006770 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous bovine bone mineral particles and non-cross-linked collagen membrane (test group)
Number of subjects: 28
Study 25006770 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncovered alveolar sockets)
Number of subjects: 28
Study 25006770 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (5 weeks)
Number of subjects: 28
Study 25006770 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 weeks)
Number of subjects: 28
Study 22456105 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Sexual intercourse after a 10-day abstinence period for 3 months
Number of subjects: 120
Study 22456105 — intervention group
Group type: COMPARATOR
Intervention: Group B: Sexual intercourse twice a week for 3 months
Number of subjects: 120
Study 20107105 — intervention group
Group type: EXPERIMENTAL
Intervention: EXE 10 microg b.i.d.
Number of subjects: 137
Study 20107105 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSI 4 mg b.i.d.
Number of subjects: 137
Study 20107105 — intervention group
Group type: EXPERIMENTAL
Intervention: EXE 10 microg b.i.d. + ROSI 4 mg b.i.d.
Number of subjects: 137
Study 18164498 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary cyclic flow variations (CCFV) group (n=14)
Number of subjects: 131
Study 18164498 — intervention group
Group type: COMPARATOR
Intervention: Non-CCFV group (n=117)
Number of subjects: 131
Study 18164498 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFV group (n=14)
Number of subjects: 131
Study 15800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Device that applies kneading-like motion on the abdomen, used once daily for 20 min for 12 weeks
Number of subjects: 30
Study 15800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Device that applies kneading-like motion on the abdomen
Number of subjects: 30
Study 12777952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate, administered once a day orally for 12 months
Number of subjects: 56
Study 12777952 — intervention group
Group type: COMPARATOR
Intervention: Control group - Normotensive PMW receiving the same HRT
Number of subjects: 56